Drug Profile
TP 271
Alternative Names: TP-271Latest Information Update: 30 Jul 2020
Price :
$50
*
At a glance
- Originator Tetraphase Pharmaceuticals
- Class Antibacterials; Fluorinated hydrocarbons; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Bacterial infections; Community-acquired pneumonia
Most Recent Events
- 28 Jul 2020 Tetraphase Pharmaceuticals has been acquired by La Jolla Pharmaceutical Company
- 12 Nov 2019 Tetraphase Pharmaceuticals plans a phase II trial for TP 271
- 26 Jun 2019 Tetraphase Pharmaceuticals plans a phase-II trial for Bacterial infections